The South America Self-Blood glucose monitoring market size is expected to increase from USD 541.45 million in 2025 to USD 565.60 million in 2026 and reach USD 703.49 million by 2031, growing at a CAGR of 4.46% over 2026-2031. This report is segmented by Component (Glucometer Devices, Test Strips, Lancets), Diabetes Type (Type 1, Type 2, Gestational), Distribution Channel (B2B, Retail Pharmacies, Online Pharmacies, Others), End-User (Homecare, Hospitals & Clinics, Diagnostics, Others), and Geography (Brazil, Argentina, Colombia, Rest of South America). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Lancets are usually bundled with other products at the point of sale. They are less likely to make a purchase decision on their own. Their quality can still affect testing regularity, especially for pediatric users, where lower pain can support use. The IDF recorded 967,187 live births affected by hyperglycemia in pregnancy in South and Central America during 2024. These pregnancies create a defined period when intensive monitoring may be needed. This demand supports the use of strips among patients managing gestational diabetes.
Type 2 diabetes held 89.24% revenue share in 2025. Its large share aligns with the broad prevalence of Type 2 diabetes across income groups in the region. Many people with Type 2 diabetes require periodic glucose checks rather than continuous monitoring. This care pattern supports sales through retail pharmacies and hospital procurement. The high patient base gives suppliers a broad volume foundation. It also leaves affordability and refill access central to regular testing.
Gestational diabetes is forecast to grow at a 7.22% CAGR through 2031. A 2024 Buenos Aires hospital study recorded gestational diabetes in 9% of pregnancies. A provincial maternity center reported an incidence rising from 16.8% in 2021 to 37.1% in 2023 after it adopted more sensitive diagnostic protocols. Wider screening in Brazil and Colombia is expected to identify more patients during pregnancy. These patients need intensive monitoring for a limited care period.
South America Self-Blood Glucose Monitoring Market Trends and Insights
Rising Diabetes Prevalence and Undiagnosed Burden
The South America self-blood glucose monitoring market is supported by the large number of adults who live with diabetes without a diagnosis. The IDF recorded 35.4 million adults with diabetes in South and Central America in 2024. It also reported that 10.7 million adults were undiagnosed, representing 30.4% of adults with diabetes. These individuals may require entry-level meters and supplies when screening identifies their condition. Brazil had 17 million people with diabetes in 2024, which made it the region’s largest source of patient demand. Screening activity converts a previously unmonitored population into people who need regular testing, although out-of-pocket costs can limit testing frequency.Public Provision and Reimbursement of SMBG Supplies
Public reimbursement gives the South America self-blood glucose monitoring market a predictable institutional sales channel. Brazil’s public health system has provided glucometers and test strips without charge to insulin-dependent patients under Portaria nº 2.583 since 2007. Product specifications in these tenders influence which suppliers can compete for public contracts. Argentine obras sociales and PAMI also support access to self-monitoring supplies, although currency depreciation raises procurement costs. Brazil’s national health technology assessment process did not add flash CGM to the public system in its January 2025 recommendation, leaving conventional monitoring supplies relevant for covered patients. Tender access can give suppliers multiyear volume visibility that is not available through retail sales alone.Accelerating CGM Adoption Among Insulin Users: Reducing Fingerstick Frequency
CGM adoption can reduce demand for frequent fingerstick testing among insulin-dependent patients in the South America self-blood glucose monitoring market. These patients often consume the highest volumes of test strips because they test more often. Chile expanded CGM coverage in December 2025 for people under 18 and pregnant women with Type 1 diabetes. Brazil is evaluating real-time CGM coverage for Type 1 diabetes through Consulta Pública 63/2026. The Brazilian real-world study found that 87.6% of flash CGM users had Type 1 diabetes. Brazil’s January 2025 decision on flash CGM indicates that the transition in the public system remains gradual.Other drivers and restraints analyzed in the detailed report include:
- Shift to Home-Based Diabetes Self-Management and Digital Enablement
- Expansion of Retail and E-Pharmacy Fulfillment
- Import Dependence, Foreign-Exchange Volatility, and Price Caps
Segment Analysis
Test strips held 82.31% of the South America self-blood glucose monitoring market share in 2025 and recorded a 5.58% CAGR through 2031. Their leading position reflects the repeated use of strips after a meter is placed. Each test requires a compatible consumable, which creates a continuing purchase cycle. Meters can be subsidized or included in reimbursement programs to encourage access. That approach can increase the installed base for a supplier’s proprietary strip format. The recurring nature of strips makes a stable supply a priority for pharmacies, public buyers, and patients.Lancets are usually bundled with other products at the point of sale. They are less likely to make a purchase decision on their own. Their quality can still affect testing regularity, especially for pediatric users, where lower pain can support use. The IDF recorded 967,187 live births affected by hyperglycemia in pregnancy in South and Central America during 2024. These pregnancies create a defined period when intensive monitoring may be needed. This demand supports the use of strips among patients managing gestational diabetes.
Type 2 diabetes held 89.24% revenue share in 2025. Its large share aligns with the broad prevalence of Type 2 diabetes across income groups in the region. Many people with Type 2 diabetes require periodic glucose checks rather than continuous monitoring. This care pattern supports sales through retail pharmacies and hospital procurement. The high patient base gives suppliers a broad volume foundation. It also leaves affordability and refill access central to regular testing.
Gestational diabetes is forecast to grow at a 7.22% CAGR through 2031. A 2024 Buenos Aires hospital study recorded gestational diabetes in 9% of pregnancies. A provincial maternity center reported an incidence rising from 16.8% in 2021 to 37.1% in 2023 after it adopted more sensitive diagnostic protocols. Wider screening in Brazil and Colombia is expected to identify more patients during pregnancy. These patients need intensive monitoring for a limited care period.
Complete Report Scope:
- By Component
- Glucometer Devices
- Test Strips
- Lancets
- By Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- By Distribution Channel
- Business-to-Business
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- By End-User
- Homecare Settings
- Hospitals and Clinics
- Diagnostic Centers
- Other End Users
- By Country
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
List of Companies Covered in this Report:
- Abbott Laboratories
- Acon Laboratories
- AgaMatrix, Inc.
- Arkray
- Ascensia Diabetes Care Holdings AG
- Beurer
- Bionime
- Embecta Corp.
- Roche
- I-Sens
- LifeScan IP Holdings, LLC
- Nipro
- Nova Biomedical
- Rossmax
- Sinocare
- Terumo
- Trividia Health, Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities and Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- ACON Laboratories, Inc.
- AgaMatrix, Inc.
- ARKRAY, Inc.
- Ascensia Diabetes Care Holdings AG
- Beurer GmbH
- Bionime Corporation
- Embecta Corp.
- F. Hoffmann-La Roche AG
- i-SENS, Inc.
- LifeScan IP Holdings, LLC
- Nipro Corporation
- Nova Biomedical
- Rossmax International Ltd.
- Sinocare Inc.
- Terumo Corporation
- Trividia Health, Inc.
